Radiology Business January 13, 2025
Telix Pharmaceuticals Ltd. has reached a deal to acquire a portfolio of potential imaging agents and other assets for up to $185 million, the company announced Monday.
Inglewood, California-based biotechnology company ImaginAb is the seller, unloading a pipeline of drug candidates, technology platform and research facility. Telix noted that the acquired assets allow for “highly specific cancer targeting” by combining “fast tumor uptake and blood clearance.”
The growing Australia-based pharma firm sees great potential in the acquisition, with drug candidates that are “highly effective for imaging and treating tumors with a broad range of radioisotopes.”
“The combination of a proprietary drug discovery platform, pipeline of promising theranostic assets and a talented team of subject matter experts will...
Today's Sponsors
Today's Sponsor